Description: A Phase 1/1B Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-Tumor Activity of PF-07220060 as a Single Agent and As Part of Combination Therapy In Participants With Advanced Solid Tumors.
Target Patient Population: Metastatic Breast Cancer, NSCLC (adeno), Prostate cancer, Colorectal cancer, Liposarcoma and tumor types with CDK4 or CCND1 amplification; in combination with letrozole/fulvestrant for HR+ HER2- breast cancer
Study Design: Drug is given orally twice daily